PFG Advisors Purchases 1,868 Shares of IQVIA Holdings Inc. $IQV

PFG Advisors lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 24.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,439 shares of the medical research company’s stock after buying an additional 1,868 shares during the period. PFG Advisors’ holdings in IQVIA were worth $1,487,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of IQV. Everpar Advisors LLC lifted its holdings in shares of IQVIA by 4.6% in the 2nd quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock worth $221,000 after acquiring an additional 62 shares during the last quarter. Private Trust Co. NA lifted its stake in IQVIA by 12.5% in the second quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock worth $95,000 after purchasing an additional 67 shares during the last quarter. Ballentine Partners LLC boosted its position in IQVIA by 4.9% during the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company’s stock valued at $260,000 after buying an additional 69 shares during the period. Independent Advisor Alliance grew its stake in shares of IQVIA by 4.2% during the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock valued at $318,000 after buying an additional 72 shares during the last quarter. Finally, Nemes Rush Group LLC increased its holdings in shares of IQVIA by 15.0% in the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company’s stock worth $109,000 after buying an additional 81 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 1.4%

Shares of IQVIA stock opened at $213.39 on Tuesday. The company’s fifty day simple moving average is $199.83 and its two-hundred day simple moving average is $176.94. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $225.00. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The company has a market cap of $36.34 billion, a P/E ratio of 29.27, a PEG ratio of 2.35 and a beta of 1.34.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. During the same quarter in the previous year, the company earned $2.84 earnings per share. IQVIA’s quarterly revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. TD Cowen lowered IQVIA from a “buy” rating to a “hold” rating and raised their price target for the stock from $206.00 to $215.00 in a research report on Monday, November 3rd. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Sunday. Mizuho lifted their target price on shares of IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Redburn Partners set a $214.00 price target on shares of IQVIA in a research report on Wednesday, September 3rd. Finally, Robert W. Baird set a $258.00 price objective on shares of IQVIA and gave the company an “outperform” rating in a research report on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $239.94.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider owned 27,108 shares in the company, valued at $5,955,627.60. This trade represents a 12.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.60% of the stock is currently owned by insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.